The significant increase in revenue forecast post-merger indicates a positive outlook for Standard BioTools. This is likely to be viewed favorably by investors, potentially leading to a short-term increase in the stock price. The merger completion and the substantial upward revision in revenue expectations suggest operational synergies and expanded market reach, which are critical factors for growth.